Centre for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia.
Clin Exp Ophthalmol. 2012 Jan-Feb;40(1):67-72. doi: 10.1111/j.1442-9071.2011.02719.x. Epub 2011 Dec 23.
To investigate the efficacy of ranibizumab therapy for choroidal neovascular (CNV) membranes secondary to conditions other than macular degeneration.
Prospective case series conducted at the Royal Victorian Eye and Ear Hospital.
Twelve-month follow-up data for 41 patients with CNV recruited from the outpatient clinic from May 2008 to April 2010 is presented. Fifteen patients had myopia, seven had multifocal choroiditis, and eight had other primary causes.
All patients had visual acuity, fluorescein angiogram and optical coherence tomography performed at the initial visit (baseline). Ranibizumab was injected with a standard sterile technique. Patients were reviewed after 1 month, and further injections were given at the treating doctors' discretion.
Change in visual acuity and central macular thickness at 12 months was compared with baseline for each of the groups. Local and systemic adverse outcomes were recorded.
Analysis was stratified by primary pathology. On average, 40%, 43% and 25% of patients with myopia, multifocal choroiditis and 'other' pathologies, respectively, experienced a three or more line improvement in vision. The average number of injections in 12 months was 4.2 for the entire group. Central macular thickness significantly decreased in the 12-month period for the combined group (P = 0.03). No patient had an adverse systemic side-effect; however, there was one case of endophthalmitis.
Ranibizumab is an effective treatment for CNV secondary to non-age-related macular degeneration causes, with most patients gaining an improvement in the first 2 months following injection.
研究雷珠单抗治疗除年龄相关性黄斑变性以外的其他原因引起的脉络膜新生血管（CNV）膜的疗效。
在皇家维多利亚眼耳医院进行的前瞻性病例系列研究。
从 2008 年 5 月至 2010 年 4 月，从门诊招募了 41 名 CNV 患者进行为期 12 个月的随访，其中 15 名患者患有近视，7 名患者患有多灶性脉络膜炎，8 名患者患有其他原发性疾病。
所有患者在初次就诊（基线）时均进行视力、荧光素血管造影和光学相干断层扫描。采用标准无菌技术注射雷珠单抗。患者在 1 个月后进行复查，并根据治疗医生的判断进行进一步注射。
比较各组患者在 12 个月时视力和中心黄斑厚度与基线的变化。记录局部和全身不良结果。
根据主要病理进行分析分层。平均而言，近视、多灶性脉络膜炎和“其他”病理患者分别有 40%、43%和 25%的患者视力提高了三行或更多行。整个组在 12 个月内的平均注射次数为 4.2 次。在 12 个月期间，联合组的中心黄斑厚度显著降低（P = 0.03）。没有患者出现全身不良反应；然而，有一例眼内炎。
雷珠单抗是治疗非年龄相关性黄斑变性引起的 CNV 的有效方法，大多数患者在注射后前 2 个月内视力得到改善。
